Unregistered Sales of Equity Securities

Business context and reporting period

Conexeu Sciences Inc. filed this Form 8-K regarding a board-approved warrant inducement program. The reported event occurred October 21, 2026; the filing was signed October 27, 2026. This is a financing and potential-dilution announcement, not a periodic financial-results filing.

Key financial and capital metrics

  • Existing Warrants: As of October 21, 2026, holders could exercise warrants for up to 4,762,780 common shares at $2.30 per share, with expirations from February 11 to June 18, 2029.
  • Inducement Warrants: For each Existing Warrant exercised by 4:00 p.m. Reno time on April 30, 2027, the holder may buy one Inducement Warrant for $0.001. Each Inducement Warrant covers one additional share at $3.00, exercisable for 24 months from issuance.
  • Share cap: Before the required Nasdaq stockholder approval, no more than 2,563,389 Inducement Warrant Shares may be issued, on a first-to-exercise basis. The cap is intended to keep the combined potential issuance from this program and the recent unit offering below Nasdaq’s 20% threshold.
  • Recent offering: The $3.00 Unit/Special Warrant private placement closed October 15, 2026, and may involve up to 1,666,667 common shares plus up to 1,666,667 shares underlying its warrants. The filing cites 29,498,365 common shares outstanding when the board authorized that offering.
  • The filing provides no revenue, profit, cash-flow, margin, debt, or liquidity figures.

Material changes and potential impact

The program offers warrant holders an incentive to exercise existing warrants earlier than their 2029 expirations. Exercise would bring cash to the company and issue common shares; the additional Inducement Warrants could create further share issuance and proceeds if exercised. Actual participation, proceeds, and dilution are not stated and are uncertain. The filing does not provide a comparable-period financial update.

Terms, risks, and other notable items

  • The company says the unit offering and potential inducement-warrant shares are aggregated under Nasdaq Listing Rules. Issuance reaching 20% or more of pre-offering shares requires stockholder approval; the Exchange Share Cap applies until that approval is obtained.
  • The board approved seeking Nasdaq Rule 5635(d) stockholder approval at an annual and/or special meeting. The filing does not state when a vote will occur or its outcome.
  • The company agreed to register certain non-affiliate holders’ Existing Warrant Shares for resale on Form S-1. Registration does not mean those shares have been sold.
  • For certain participating holders subject to existing pooling agreements, the Existing Warrant Shares, Inducement Warrants, and Inducement Warrant Shares remain pooled until May 21, 2027, 12 months after the company’s Nasdaq listing.
  • Some holders are subject to 4.99% or 9.99% beneficial-ownership limits on Inducement Warrant Shares.
  • The securities are being offered under exemptions from registration and will bear restrictive legends; resale requires registration or an applicable exemption.

Important facts for investors to verify

  • How many Existing Warrants are exercised during the early-exercise period and the cash proceeds received.
  • Whether stockholders approve issuance above the Exchange Share Cap, and the resulting share count and dilution.
  • How many Inducement Warrants are issued and later exercised, including any shares issued under the cap.
  • The final terms in the filed warrant and subscription documents, and the status and scope of the Form S-1 resale registration.
  • Any subsequent company disclosures on liquidity, financial performance, and use of proceeds; this filing does not report those items.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.